Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)

af Abou-Alfa, Ghassan K., Yen, Chia-Jui, Hsu, Chih-Hung, O’Donoghue, Joseph, Beylergil, Volkan, Ruan, Shutian, Pandit-Taskar, Neeta, Gansukh, Bolorsukh, Lyashchenko, Serge K., Ma, Jennifer, Wan, Peter, Shao, Yu-Yun, Lin, Zhong-Zhe, Frenette, Catherine, O’Neil, Bert, Schwartz, Lawrence, Smith-Jones, Peter M., Ohtomo, Toshihiko, Tanaka, Takayoshi, Morikawa, Hideo, Maki, Yuko, Ohishi, Norihisa, Chen, Ya-Chi, Agajanov, Tamara, Boisserie, Frederic, Di Laurenzio, Laura, Lee, Ray, Larson, Steven M., Cheng, Ann-Lii, Carrasquilo, Jorge A.
Udgivet i Cancer Chemother Pharmacol (2017)